Phase 4 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a successful TEER procedure, meaning the procedure met standard technical success criteria.
- People who are willing and able to follow the trial's requirements and schedule.
- People who have provided written consent to participate.
- Women who could become pregnant must be using effective contraception from the time of consent until the end of antithrombotic (blood-thinning) treatment.
- People whose blood-thinning medication plan has been reviewed and approved by the trial investigator.
Who may not be able to join:
- People with severely reduced kidney function (very low kidney clearance rate or currently on dialysis).
- People who are experiencing significant ongoing bleeding or serious blood vessel complications following their TEER procedure.
- People with a very low platelet count (the blood cells that help with clotting) below a certain level.
- People who need a repeat operation because of complications from their TEER procedure.
- People who have had bleeding inside the brain or skull within the past 12 months.
- People who have had stomach or bowel ulcers or bleeding within the past 12 months.
- People with liver disease that affects their blood's ability to clot (such as moderate or severe liver cirrhosis).
- People who are allergic to, cannot tolerate, or have a medical reason not to take the study medications.
- People who have participated in another clinical drug or device trial within the past 30 days.
- People who require long-term use of blood-thinning medication (oral anticoagulants) for another condition.
- People who must take two antiplatelet (anti-clotting) medications together for another condition, such as after a recent heart stent procedure.
- People with a life expectancy of less than 12 months.
- People who are pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiangbin Pan, MD,PhD, Chinese Academy of Medical Sciences, Fuwai Hospital
Phone: +86(10)88396666
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All bleeding complications at 1 year after TEER
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.